SBL
EDIT icon

Sargent Bickham Lagudis’s Editas Medicine EDIT Stock Holding History

Sargent Bickham Lagudis’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$887 Buy
+100
New +$1.1K ﹤0.01% 974
2021
Q2 		– Sell
-200
Closed -$8K – 942
2021
Q1 		$8K Hold
200
– – ﹤0.01% 737
2020
Q4 		$14K Hold
200
– – ﹤0.01% 608
2020
Q3 		$6K Buy
+200
New +$6.51K ﹤0.01% 642

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sargent Bickham Lagudis's EDIT Position: Q4 2022 in Review

Sargent Bickham Lagudis opened a new position in Editas Medicine (EDIT) in Q4 2022: 100 shares worth $887. The stake represents ﹤0.01% of the portfolio and ranks #974 among its holdings. This is a return to the name: Sargent Bickham Lagudis previously reported a position in EDIT as recently as Q1 2021.

Sargent Bickham Lagudis first reported a position in EDIT in Q3 2020 and has held it in 4 quarters since. The position peaked at $14K in Q4 2020. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

  • Sargent Bickham Lagudis held 100 shares of Editas Medicine worth $887 as of Q4 2022.
  • Editas Medicine was a new Sargent Bickham Lagudis position in Q4 2022.
  • Editas Medicine made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #974 holding.
  • Sargent Bickham Lagudis first reported a position in Editas Medicine in Q3 2020 and has held it in 4 quarters since.
  • Sargent Bickham Lagudis's Editas Medicine position peaked at $14K in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.